Home・Список акций・Alvotech SA

Alvotech SA

Открыт

СекторЗдравоохранение

4.05 -0.74

Купить Продать

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

3.98

Макс.

4.13

Ключевые показатели
By Trading Economics
Доход	110M 1M
Продажи	-60M 106M
P/E Средняя по отрасли	42.4 57.002
Прибыль на акцию	-0.09
Рентабельность продаж	0.973
Сотрудники	1,279
EBITDA	167M 52M

Рекомендации
By TipRanks
Рекомендации	Продажа
Прогноз на 12 месяцев	-2.2% downside

Дивиденды
By Acuity
Следующий отчет о доходах	19 авг. 2026 г.

Рыночная статистика
By TradingEconomics
Рыночная капитализация	261M 1.3B
Предыдущая цена открытия	4.79
Предыдущая цена закрытия	4.05

Новостные настроения

By Acuity

40%

60%

134 / 340 Рейтинг в Healthcare

Alvotech SA График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

13 авг. 2026 г., 20:06 UTC

Alvotech SA shares are higher during Thursday's session, continuing an upward trend since Wednesday's close, trading above its 20-day moving average.

12 авг. 2026 г., 19:31 UTC

Alvotech SA shares are trading higher, reflecting market optimism after recent inflation data showed core CPI aligned with forecasts. No specific company news was identified.

11 авг. 2026 г., 19:26 UTC

News

Alvotech's Reykjavik facility receives Voluntary Action Indicated status from the FDA, allowing advancement of multiple Biologics License Applications. Shares are trading higher.

10 авг. 2026 г., 20:06 UTC

News

Alvotech SA will release its financial results for the first half of 2026 on August 19, after the U.S. market close. Shares are little changed.

6 авг. 2026 г., 20:06 UTC

Alvotech SA shares are higher today, trading above their 20-day moving average and near the upper end of their one-month range. No specific news was identified.

5 авг. 2026 г., 19:56 UTC

Alvotech SA shares are lower during Wednesday's session, continuing a decline since Tuesday's close amid broader market trends and falling oil prices.

4 авг. 2026 г., 19:52 UTC

Alvotech SA shares are higher today, supported by declining crude oil prices easing inflation concerns. The stock remains above its 20-day moving average.

3 авг. 2026 г., 19:51 UTC

Alvotech SA shares are lower today, reflecting a sharp decline despite a brief rebound earlier in the session. No specific news was identified for the drop.

31 июл. 2026 г., 21:02 UTC

Alvotech SA shares declined in after-market trading, reversing six days of gains. No specific news was identified to explain the price movement.

30 июл. 2026 г., 20:10 UTC

Alvotech SA shares are higher during Thursday's session, reflecting broader market movements amid mixed economic signals and maintaining a position above the 20-day moving average.

29 июл. 2026 г., 19:04 UTC

News

Social Media

Alvotech SA's FDA inspection results in a Voluntary Action Indicated classification. Shares are trading higher as the company advances its biosimilar pipeline.

28 июл. 2026 г., 19:56 UTC

Alvotech SA shares are higher today, reaching a high of 6.17%. The stock remains below its 20-day moving average with no specific news identified.

27 июл. 2026 г., 19:31 UTC

Alvotech SA shares are higher today, rebounding from an earlier session low. This follows a positive trend since Friday's close amid declining oil prices.

24 июл. 2026 г., 19:51 UTC

Alvotech SA shares are lower today, continuing a trend of weakness amid broader market pressures and three consecutive lower daily closes.

22 июл. 2026 г., 18:31 UTC

Alvotech SA shares are lower, continuing a decline since Tuesday. Broader market sentiment is impacted by geopolitical tensions and rising crude oil prices.

21 июл. 2026 г., 19:16 UTC

Alvotech SA shares are higher during Tuesday's session amid a broader market recovery, driven by renewed interest in AI stocks and upcoming tech earnings.

20 июл. 2026 г., 19:31 UTC

Alvotech SA shares are lower today, with no specific news identified. Broader market weakness includes a decline in the US 10Y Treasury Bond index.

Сравнение c конкурентами

Изменение цены

Alvotech SA Прогноз

Целевая цена

By TipRanks

-2.2% падение

Прогноз на 12 месяцев

Средняя 4 USD -2.2%

Максимум 4 USD

Минимум 4 USD

Основано на мнении 1 аналитиков Wall Street, спрогнозировавших целевые цены для Alvotech SA на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Продажа

1 ratings

Покупка

Удержание

Продажа

Основано на мнении 1 аналитиков, присваивавших рейтинги акциям Alvotech SA – Данные за последние 3 месяца.

Настроения

By Acuity

134 / 340Рейтинг в Здравоохранение

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

О компании Alvotech SA

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an Keytruda product. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.